Interferon alpha-2

BIOLOGICAL8 trials

Sponsors

Roswell Park Cancer Institute, Center for Genetic Engineering and Biotechnology (CIGB), in Havana, Center for Genetic Engineering and Biotechnology (CIGB)

Conditions

Acute respiratory infection (ARI)Anatomic Stage IV Breast Cancer AJCC v8COVID-19 COVID-19 SARS-CoV-2Metastatic Triple-Negative Breast CarcinomaPharmacodynamics and safety in healthy volunteers pharmacodynamicsProphylaxis of SARS-CoV-2 infection COVID-19 SARS-CoV2Unresectable Triple-Negative Breast Carcinomaacute respiratory infection

Phase 1

Pharmacodynamics of the Nasalferon in healthy volunteers.

Active, not recruitingRPCEC00000308

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaPharmacodynamics and safety in healthy volunteers pharmacodynamics

Start: 2020-05-04Target: 30Updated: 2026-03-30

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

TerminatedNCT05756166

Roswell Park Cancer InstituteAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma

Start: 2024-02-16End: 2025-06-19Updated: 2025-06-24

Phase 2

ESPERANZA study

RecruitingRPCEC00000307

Center for Genetic Engineering and Biotechnology (CIGB), in Havanapatients infected with the SARS-CoV-2 coronavirus. covid-19

Start: 2020-04-10Target: 120Updated: 2026-03-30

Active, not recruitingRPCEC00000337

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaProphylaxis of SARS-CoV-2 infection COVID-19 SARS-CoV2

Start: 2020-10-12Target: 80Updated: 2026-03-30

Phase 3

Nasalferon in COVID-19

Active, not recruitingRPCEC00000399

Center for Genetic Engineering and Biotechnology (CIGB)COVID-19 COVID-19 SARS-CoV-2

Start: 2021-11-22Target: 128Updated: 2026-03-30

Nasalferon in ARI

Active, not recruitingRPCEC00000407

Center for Genetic Engineering and Biotechnology (CIGB)Acute respiratory infection (ARI)

Start: 2022-09-01Target: 495Updated: 2026-03-30

Nasal recombinant human interferon alfa-2b in ARI

Active, not recruitingRPCEC00000412

Center for Genetic Engineering and Biotechnology (CIGB)acute respiratory infection

Start: 2023-02-01Target: 608Updated: 2026-03-30

Unknown Phase

Expanded Clinical Use of Nasalferon in COVID-19

Active, not recruitingRPCEC00000396

Center for Genetic Engineering and Biotechnology (CIGB)COVID-19 COVID-19 SARS-CoV-2

Start: 2021-11-15Target: 200Updated: 2026-03-30